{
    "nctId": "NCT01658462",
    "briefTitle": "Phase II Study of Docetaxel +/- Nintedanib in Breast Cancer",
    "officialTitle": "A Phase II Randomized Study of Docetaxel With or Without NINTEDANIB (BIBF-1120) in Patient Receiving a First or Second-line of Chemotherapy for HER Negative Metastatic or Locally Recurrent Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 51,
    "primaryOutcomeMeasure": "Progression free survival (PFS) in patients receiving Docetaxel + Nintedanib treatment (Arm A) compared to Docetaxel alone (Arm B)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Age \u2265 18 years old\n* Histologically or cytologically confirmed adenocarcinoma of the breast\n* Locally recurrent or metastatic disease\n* HER 2 negative status\n* Requiring a first or a second-line chemotherapy for locally recurrent or metastatic disease.\n* Prior first line chemotherapy not containing Docetaxel\n* Measurable or evaluable disease according to RECIST 1.1 criteria\n* Allowed prior chemotherapy as follows :\n\n  * Docetaxel in the neoadjuvant or adjuvant setting is allowed provided that relapse has been observed more than 12 months after the end of docetaxel treatment\n  * Bevacizumab in 1st line is allowed with a wash-out of 4 weeks, with recovery to NCI-CTCAE v3.0 toxicity\n* ECOG performance status 0-1\n* Adequate bone marrow, hepatic and renal functions as evidence by the following:\n\n  * Hemoglobin \u2265 10 G/100 mL\n  * Neutrophils count \u2265 1500 /mm3\n  * Platelets \u2265 100 000 /mm3\n  * Total bilirubin \u2264 ULN (ULN:Upper Limit of Normal)\n  * SGOT/SGPT \u2264 1.5 x ULN (\u2264 2.5 x ULN in case of hepatic metastasis)\n  * Serum alkaline phosphatase \u2264 2.5 x ULN\n  * Creatinin clearance \u2265 45 ml/min or creatinin \u2264 1.5 x ULN\n  * Proteinuria \\< CTCAE grade 2\n* Coagulation parameters: International normalised ratio (INR) \u2264 2, prothrombin time (PT) and partial thromboplastin time (PTT) \u2264 50% of deviation of institutional ULN\n* Effective contraception for patients (male and female) with reproductive potential during their entire participation in the study and during 3 months after the last administration of Nintedanib or Docetaxel\n* Negative pregnancy test (serum beta-HCG) performed within 1 week prior to start of study treatment in females with reproductive potential\n* Patient covered by government health insurance\n* Signed and dated written informed consent prior to admission to the study in accordance with ICH-GCP guidelines and to the local legislation\n\nExclusion Criteria:\n\n* Concomitant hormone therapy for metastatic breast cancer\n* Patients with dysphagia, or inability to swallow the tablets\n* Other serious illness or medical conditions: Cardiac disease\n* Unstable diabetes\n* Uncontrolled hypercalcemia\n* Pregnancy or breast feeding woman\n* Unable for medical follow-up (geographic, social or mental reasons)\n* Prior treatment with Nintedanib or any other VEGFR inhibitor\n* Known hypersensitivity to the trial drugs , to their excipients, to peanut, to soya or to contrast media\n* Contra indication to the use of the backbone treatment and to the comparator\n* Active brain metastases (e.g. stable for \\<4 weeks, no adequate previous treatment with radiotherapy, symptomatic, requiring treatment with anti-convulsants; dexamethasone therapy will be allowed if administered as stable dose for at least one month before randomisation)\n* Leptomeningeal disease\n* Radiographic evidence of cavitary or necrotic tumors\n* Centrally located tumors with radiographic evidence (CT or MRI) of local invasion of major blood vessels\n* History of clinically significant haemorrhagic or thromboembolic event in the past 6 months\n* Known inherited predisposition to bleeding or thrombosis\n* Significant cardiovascular diseases ( i.e. uncontrolled hypertension, unstable angina, history of infarction within the past 12 months prior to start of study treatment, congestive heart failure \\> NYHA II, serious cardiac arrhythmia, pericardial effusion)\n* Other malignancies within the past 5 years other than basal cell skin cancer or carcinoma in situ of the cervix\n* Active serious infections in particular if requiring systemic antibiotic or antimicrobial therapy\n* Active or chronic hepatitis C and/or B infection\n* Active alcohol or drug abuse\n* Significant weight loss (\\> 10% of BW) within past 6 months prior to inclusion into the trial",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}